PAM
GEVA

Paradigm Asset Management’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

Paradigm Asset Management’s Portfolio GEVA Stock Details GEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-5,400
Closed -$501K – 883
2014
Q4 		$501K Sell
5,400
-27,800
-84% -$2.19M 0.06% 307
2014
Q3 		$2.28M Buy
+33,200
New +$2.38M 0.32% 103

Other funds holding GEVA

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Paradigm Asset Management's GEVA Position: Q1 2015 in Review

Paradigm Asset Management sold out of SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q1 2015, closing a stake of 5,400 shares — an estimated $501K sold.

Paradigm Asset Management first reported a position in GEVA in Q3 2014 and held it in 2 quarters. The position peaked at $2.28M in Q3 2014. 130 funds tracked by Wall St. Rank hold GEVA as of Q1 2015.

  • Paradigm Asset Management reported no remaining SYNAGEVA BIOPHARMA CORP COM STK (DE) position as of Q1 2015 after selling out during the quarter.
  • Paradigm Asset Management sold 5,400 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q1 2015, an estimated $501K.
  • Paradigm Asset Management first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q3 2014 and held it in 2 quarters.
  • Paradigm Asset Management's SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $2.28M in Q3 2014.
  • 130 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q1 2015.

Based on Paradigm Asset Management's 13F filing for Q1 2015, filed 14 May 2015.